CL2024004012A1 - Anticuerpos monoclonales anti-slc34a2 y sus usos - Google Patents

Anticuerpos monoclonales anti-slc34a2 y sus usos

Info

Publication number
CL2024004012A1
CL2024004012A1 CL2024004012A CL2024004012A CL2024004012A1 CL 2024004012 A1 CL2024004012 A1 CL 2024004012A1 CL 2024004012 A CL2024004012 A CL 2024004012A CL 2024004012 A CL2024004012 A CL 2024004012A CL 2024004012 A1 CL2024004012 A1 CL 2024004012A1
Authority
CL
Chile
Prior art keywords
slc34a2
monoclonal antibodies
antibodies
binding
adcc
Prior art date
Application number
CL2024004012A
Other languages
English (en)
Spanish (es)
Inventor
Li Runsheng
Huang Wentao
Li Yifan
Original Assignee
Lanova Medicines Dev Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lanova Medicines Dev Co Ltd filed Critical Lanova Medicines Dev Co Ltd
Publication of CL2024004012A1 publication Critical patent/CL2024004012A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2024004012A 2022-06-22 2024-12-23 Anticuerpos monoclonales anti-slc34a2 y sus usos CL2024004012A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2022100315 2022-06-22

Publications (1)

Publication Number Publication Date
CL2024004012A1 true CL2024004012A1 (es) 2025-05-02

Family

ID=89379184

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024004012A CL2024004012A1 (es) 2022-06-22 2024-12-23 Anticuerpos monoclonales anti-slc34a2 y sus usos

Country Status (14)

Country Link
US (2) US12215150B2 (cg-RX-API-DMAC10.html)
EP (1) EP4543926A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025520692A (cg-RX-API-DMAC10.html)
KR (1) KR20250051643A (cg-RX-API-DMAC10.html)
CN (1) CN119948054A (cg-RX-API-DMAC10.html)
AU (1) AU2023289743A1 (cg-RX-API-DMAC10.html)
CA (1) CA3260354A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024004012A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024017740A2 (cg-RX-API-DMAC10.html)
IL (1) IL317849A (cg-RX-API-DMAC10.html)
MX (1) MX2025000053A (cg-RX-API-DMAC10.html)
PE (1) PE20252048A1 (cg-RX-API-DMAC10.html)
TW (1) TW202409076A (cg-RX-API-DMAC10.html)
WO (1) WO2023246879A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024408814A1 (en) * 2023-12-21 2026-07-09 LaNova Medicines Limited Conjugates of anti-slc34a2 antibody and uses thereof
CN120988123B (zh) * 2025-10-21 2026-03-17 苏州近岸蛋白质科技股份有限公司 一种抗人NaPi2b的人源化单克隆抗体及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2250201B1 (en) 2008-01-29 2014-04-30 Ludwig Institute for Cancer Research Ltd. Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

Also Published As

Publication number Publication date
US20250154248A1 (en) 2025-05-15
CA3260354A1 (en) 2023-12-28
EP4543926A1 (en) 2025-04-30
CN119948054A (zh) 2025-05-06
JP2025520692A (ja) 2025-07-03
IL317849A (en) 2025-02-01
US12215150B2 (en) 2025-02-04
CO2024017740A2 (es) 2025-05-19
KR20250051643A (ko) 2025-04-17
MX2025000053A (es) 2025-04-02
US20240301052A1 (en) 2024-09-12
TW202409076A (zh) 2024-03-01
WO2023246879A1 (en) 2023-12-28
PE20252048A1 (es) 2025-08-21
AU2023289743A1 (en) 2025-01-09

Similar Documents

Publication Publication Date Title
CL2023001076A1 (es) Anticuerpos monoclonales anti-ccr8 y sus usos.
CO2024017740A2 (es) Anticuerpos monoclonales anti-slc34a2 y sus usos
MX2022003517A (es) Anticuerpos anti-pd l1 y conjugados de anticuerpo-farmaco.
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
CO2020014345A2 (es) Anticuerpos específicos para gucy2c y sus usos
CO2019003923A2 (es) Anticuerpos anti-steap2, conjugados anticuerpo-fármaco, y moléculas de fijación al antígeno biespecíficas que se fijan a steap2 y cd3, y usos de estos
EA202092306A1 (ru) Анти-cd24 композиции и их применения
MX2020012286A (es) Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t.
CO2021006248A2 (es) Anticuerpos anti-nkg2a y usos de los mismos
DOP2024000036A (es) Anticuerpos anti-psma y usos de estos
BR112021015477A2 (pt) Anticorpos anti-cd228 e conjugados anticorpo-fármaco
JOP20190116A1 (ar) الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
CO2021011944A2 (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer
CO2022001195A2 (es) Anticuerpos dirigidos contra dll3 y usos de los mismos
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
MX2017012278A (es) Anticuerpos anti-ceacam6 y sus usos.
AR106570A1 (es) Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos
DOP2012000052A (es) Proteínas terapéuticas de unión a dll4
CY1109525T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
CO2022019161A2 (es) Tubulisinas y conjugados de proteína-tubulisina
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
CY1124183T1 (el) Συζευγματα αντισωματος εναντι-sez6 φαρμακου και μεθοδοi χρησης
AR111362A1 (es) Anticuerpos anti-ilt4 y fragmentos de unión a antígeno
MX2022002672A (es) Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo.